Glaxo submits Promacta sNDA; NICE denies Alimta in expanded lung cancer use; Merck KGaA ups its dividend;

@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma

@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton

@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce

@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) has submitted a supplemental New Drug Application to the FDA for anemia drug Promacta. More

> Merck KGaA will hike its dividend to €1.90 a share. Report

> The U.K.'s cost-effectiveness watchdog has shot down an expanded lung cancer indication for Eli Lilly's ($LLY) Alimta. Report

> Arena ($ARNA), maker of obesity drug Belviq, saw its fourth-quarter net losses widen to $0.11 per share. News

> The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a new tablet formulation of Merck's ($MRK) antifungal Noxafil. More

Medical Device News

@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev

@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce

@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce

> HeartWare's heart pump revenue jumped in Q4, thanks to U.S. growth. News

> Illumina's prenatal blood test shows standout results in NEJM. More

> S. Korea is trying to decide whether the Galaxy S5 is a medical device. Story

Biotech News

@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech

@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce

@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce

@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce

> Celgene gambles $50M on Abide and its R&D work on enzyme 'superfamily'. More

> Bayer plans to ratchet up its R&D spend and chase down some deals. Article

And Finally... Novartis ($NVS), Sanofi's ($SNY) Genzyme, Alexion ($ALXN) and others have joined the global rare disease community in recognition of Friday's Rare Disease Day. More

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.